HSR

UnitedLex Launches RAPID Review, Accelerating Review Process by 75% with a 98% Quality Assurance Guarantee

Retrieved on: 
Wednesday, October 11, 2023
PXI, Regular expression, Lawsuit, RAPID, EDI, AI, HIPAA, Intellectual property, Risk, DOJ, Legal defense fund, Rapid Reviews: Infectious Diseases, HSR, Medical device

The optimized review model reduces the need for eyes-on review and continues to modernize how litigation and review teams leverage machine learning to do their jobs faster, more efficiently, and with less cost and risk.

Key Points: 
  • The optimized review model reduces the need for eyes-on review and continues to modernize how litigation and review teams leverage machine learning to do their jobs faster, more efficiently, and with less cost and risk.
  • Key differentiators of RAPID Review include:
    The RAPID Report which outlines defensibility, ranking, elusion testing, and matter-specific details.
  • “RAPID Review is one of the first products to come out of our innovation lab and demonstrates how AI is positively impacting how lawyers litigate,” said Savitha Masson, VP, UnitedLex.
  • RAPID Review met DOJ requirements and deadlines while saving the client $3.5 million and 60,000 review hours.

Boundless Bio Presents Preclinical Data on the Discovery of its Second ecDNA-Directed Therapeutic Candidate, BBI-825, at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Friday, October 13, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Neoplasm, RNR, Biology, AACR, Deoxyribonucleotide, DNA, A-DNA, Bio, IND, Survival, CRC, Boundless, Patient, Preclinical imaging, Growth, Colorectal cancer, Drug discovery, MAPK, Conference, Investigational New Drug, HSR, Spyglass, Medical imaging, Pharmaceutical industry, Cytidine monophosphate

BBI-825 is a novel, orally available, selective inhibitor of ribonucleotide reductase (RNR), which is a rate-limiting enzyme in the cellular production of deoxynucleotide triphosphates (dNTPs), essential building blocks for ecDNA assembly and repair in cancer cells.

Key Points: 
  • BBI-825 is a novel, orally available, selective inhibitor of ribonucleotide reductase (RNR), which is a rate-limiting enzyme in the cellular production of deoxynucleotide triphosphates (dNTPs), essential building blocks for ecDNA assembly and repair in cancer cells.
  • BBI-825 has demonstrated RNR inhibition in a host of tumor cell lines and tumor regressions in ecDNA-enabled preclinical cancer models and is currently being evaluated in Investigational New Drug (IND)-enabling studies.
  • BBI-825 was discovered using Boundless Bio’s proprietary Spyglass platform, a drug discovery engine to identify and preclinically validate targets that are essential for cancer cells’ reliance on ecDNA for growth, treatment resistance, and survival.
  • Details of today’s presentations are as follows:
    Title: A novel, potent and selective ribonucleotide reductase (RNR) inhibitor, BBI-825, blocks extrachromosomal DNA (ecDNA) amplification-mediated resistance to KRASG12C inhibitor in colorectal cancer (CRC)

MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTech to develop next-generation anti-cancer antibody-drug conjugate

Retrieved on: 
Thursday, October 12, 2023
HIV disease progression rates, Breast cancer, Safety, Lung cancer, Cancer, BioNTech, Immunotherapy, HER3, ADC, BNTX, Hart–Scott–Rodino Antitrust Improvements Act, HSR, Vaccine

Under the terms of the agreement, MediLink will grant BioNTech exclusive global rights for the development, manufacturing, and commercialization of one of MediLink's ADC assets excluding Mainland China, Hong Kong Special Administrative Region, and Macau Special Administrative Region.

Key Points: 
  • Under the terms of the agreement, MediLink will grant BioNTech exclusive global rights for the development, manufacturing, and commercialization of one of MediLink's ADC assets excluding Mainland China, Hong Kong Special Administrative Region, and Macau Special Administrative Region.
  • In exchange, BioNTech will provide MediLink with an upfront payment totaling of $70 million and additional development, regulatory and commercial milestone payments potentially totaling over $1 billion.
  • The completion of the agreement is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino ("HSR") Antitrust Improvements Act.
  • Furthermore, HER3 expression is upregulated after frontline drug therapy, making it an adequate target for cancer treatment.

HOUSING STARTS FLAT IN MAJOR MARKETS FOR FIRST HALF OF 2023

Retrieved on: 
Thursday, October 5, 2023
CMHC, Government, Real, SGE, GST, Local government in Canada, Legislation, City, HAF, Goods and services tax (Canada), Goods, Department of Finance Canada, Consumption tax, HSR, Real estate

This contrasts with Montréal, which is more reflective of the current, more challenging, context, such as higher financing and construction costs."

Key Points: 
  • This contrasts with Montréal, which is more reflective of the current, more challenging, context, such as higher financing and construction costs."
  • On September 21, 2023, the Government of Canada introduced legislation that would remove the federal component of the Goods and Services Tax (GST) on new purpose-built rental housing projects.
  • The HAF is a $4 billion application-based initiative designed to help cities, towns, and Indigenous governments unlock new housing supply.
  • CMHC's housing starts data for July and August, 2023, shows a continuation of the overall trend observed in this report as new home construction remained relatively flat at the national level.

Earthstone Announces Expiration of Hart-Scott-Rodino Act Waiting Period in Connection with Proposed Transaction

Retrieved on: 
Tuesday, October 3, 2023
Permian, HSR, Energen Resources Corporation, NYSE, EDT, Hart–Scott–Rodino Antitrust Improvements Act, News, Retail, Cryptocurrency

THE WOODLANDS, Texas, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Earthstone Energy, Inc. (NYSE: ESTE) (“Earthstone”, the “Company”), today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), with respect to the previously-announced agreement for Permian Resources Corporation (NYSE: PR) (“Permian Resources”) to acquire all outstanding shares of Earthstone at an exchange ratio of 1.446 shares of Permian Resources for each Earthstone share.

Key Points: 
  • THE WOODLANDS, Texas, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Earthstone Energy, Inc. (NYSE: ESTE) (“Earthstone”, the “Company”), today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), with respect to the previously-announced agreement for Permian Resources Corporation (NYSE: PR) (“Permian Resources”) to acquire all outstanding shares of Earthstone at an exchange ratio of 1.446 shares of Permian Resources for each Earthstone share.
  • The expiration of the HSR Act waiting period occurred at 11:59 p.m. EDT on October 2, 2023, which was a condition to the closing of the pending transaction.
  • Completion of the transaction is subject to the satisfaction of the remaining customary closing conditions, including approval by Earthstone stockholders.
  • The Earthstone special meeting is scheduled to be held on Monday October 30, 2023 at 10:00 AM.

Asia Pacific View's "Skill-Show" by Foreign Bloggers at Vocational Skills Competition of the People's Republic of China in Tianjin

Retrieved on: 
Friday, September 22, 2023
HSR, Vocational education, Silver, IC, VR, Gardening, Republic, Occupation, City, AI, Aircraft, Industrial design

Three bloggers, Kevin, Lily, and Daria, transformed into skilled talents and experienced a variety of unique occupations in China at the Second Vocational Skills Competition of the People's Republic of China in Tianjin.

Key Points: 
  • Three bloggers, Kevin, Lily, and Daria, transformed into skilled talents and experienced a variety of unique occupations in China at the Second Vocational Skills Competition of the People's Republic of China in Tianjin.
  • A total of 109 disciplines have been set up in this vocational skills competition, with a total of 4,045 competitors from all over China participating.
  • Among them, there are experienced "masters" and young "craftsmen" who are eager to create a new peak in their vocational skills.
  • The winners will represent China in the 47th World Skills Competition to be held in Lyon, France in September next year.

Asia Pacific View's "Skill-Show" by Foreign Bloggers at Vocational Skills Competition of the People's Republic of China in Tianjin

Retrieved on: 
Friday, September 22, 2023
HSR, Vocational education, Silver, IC, VR, Gardening, Republic, Occupation, City, AI, Aircraft, Industrial design

Three bloggers, Kevin, Lily, and Daria, transformed into skilled talents and experienced a variety of unique occupations in China at the Second Vocational Skills Competition of the People's Republic of China in Tianjin.

Key Points: 
  • Three bloggers, Kevin, Lily, and Daria, transformed into skilled talents and experienced a variety of unique occupations in China at the Second Vocational Skills Competition of the People's Republic of China in Tianjin.
  • A total of 109 disciplines have been set up in this vocational skills competition, with a total of 4,045 competitors from all over China participating.
  • Among them, there are experienced "masters" and young "craftsmen" who are eager to create a new peak in their vocational skills.
  • The winners will represent China in the 47th World Skills Competition to be held in Lyon, France in September next year.

Denbury Announces Expiration of Hart-Scott-Rodino Act Waiting Period in Connection with Proposed Transaction

Retrieved on: 
Tuesday, September 12, 2023
Alternative Energy, Energy, Oil, Gas, ExxonMobil, Hart–Scott–Rodino Antitrust Improvements Act, HSR, Inc., DEN, NYSE, EDT, Pharmaceutical industry, Retail, Payment card, Denbury

Denbury Inc. (NYSE: DEN) (“Denbury”) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), with respect to the previously-announced agreement for ExxonMobil to acquire all outstanding shares of Denbury at an exchange ratio of 0.84 shares of ExxonMobil for each Denbury share.

Key Points: 
  • Denbury Inc. (NYSE: DEN) (“Denbury”) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), with respect to the previously-announced agreement for ExxonMobil to acquire all outstanding shares of Denbury at an exchange ratio of 0.84 shares of ExxonMobil for each Denbury share.
  • The expiration of the HSR Act waiting period occurred at 11:59 p.m. EDT on September 11, 2023, which was a condition to the closing of the pending transaction.
  • Completion of the transaction is subject to the satisfaction of the remaining customary closing conditions, including approval by Denbury stockholders.
  • The transaction is expected to close in the fourth quarter of 2023.

Heritage-Crystal Clean, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition by J.F. Lehman & Company

Retrieved on: 
Wednesday, September 6, 2023
Environment, Oil, Gas, Manufacturing, Green Technology, Energy, Other Manufacturing, HSR, Hart–Scott–Rodino Antitrust Improvements Act, Pharmaceutical industry, Rare-earth element

Heritage-Crystal Clean, Inc. (Nasdaq: HCCI) (“Crystal Clean” or the “Company”) today announced the expiration of the waiting period under the Hart-Scott-Rodino (“HSR”) Antitrust Improvements Act of 1976, with respect to the previously announced agreement for Crystal Clean to be acquired by an investment affiliate of J.F.

Key Points: 
  • Heritage-Crystal Clean, Inc. (Nasdaq: HCCI) (“Crystal Clean” or the “Company”) today announced the expiration of the waiting period under the Hart-Scott-Rodino (“HSR”) Antitrust Improvements Act of 1976, with respect to the previously announced agreement for Crystal Clean to be acquired by an investment affiliate of J.F.
  • Lehman & Company (“JFLCO”) for $45.50 per share in cash, or approximately $1.2 billion.
  • The expiration of the HSR waiting period occurred at 11:59 p.m. on September 1, 2023, which was a condition to the closing of the pending transaction.
  • The transaction is expected to close in the fourth quarter of 2023, subject to the satisfaction of the remaining customary closing conditions, including approval by Crystal Clean stockholders.

Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics

Retrieved on: 
Tuesday, September 5, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, HSR, Hart–Scott–Rodino Antitrust Improvements Act, CTX, Gallbladder, Asset purchase agreement, Jay Traver, Liver disease, Medication, Acquisition, DSM-IV codes, Patient, Rare, Therapy, Pharmaceutical industry, Spiroplasma mirum, Cholic acid

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the completion of Mirum’s previously announced acquisition of Travere’s bile acid product portfolio that includes Cholbam® (cholic acid) and Chenodal® (chenodiol), two medications addressing rare diseases in high-need settings (the “Asset Purchase”).

Key Points: 
  • Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the completion of Mirum’s previously announced acquisition of Travere’s bile acid product portfolio that includes Cholbam® (cholic acid) and Chenodal® (chenodiol), two medications addressing rare diseases in high-need settings (the “Asset Purchase”).
  • In connection with the closing of the Asset Purchase, Travere received an upfront payment of $210 million from Mirum, and remains eligible to receive up to $235 million in potential sales-based milestone payments.
  • The closing of the Asset Purchase was subject to the satisfaction of customary closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976.
  • In connection with the closing, Travere will provide certain transitional services to Mirum.